<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04048863</url>
  </required_header>
  <id_info>
    <org_study_id>US-N-H-1801</org_study_id>
    <nct_id>NCT04048863</nct_id>
  </id_info>
  <brief_title>Effect of B. Braun Peripheral Advantage Program on Complications, Indwell Time and First Stick Success of PIVC Therapy</brief_title>
  <official_title>Assessment of the Effect of B. Braun Peripheral Advantage Program on Complications, Indwell Time and First Stick Success of PIVC Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Medical Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single sequence clinical study designed to evaluate the effectiveness of B. Braun PA on
      improved clinical outcomes, indwell time and first stick success of PIVC using B. Braun
      Peripheral Advantage (PA) by Registered Nurses (RNs).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study will be divided into 4 Stages: 3 Clinical Stages and 1 Educational Stage.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of complications associated with PIVC use</measure>
    <time_frame>Through study completion, an estimate of 1 year</time_frame>
    <description>Evaluate the impact of B. Braun Peripheral Advantage (PA) Program on the incidence of complications associated with PIVC use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Catheter indwell time</measure>
    <time_frame>Through study completion, an estimate of 1 year</time_frame>
    <description>Evaluate the effect of B. Braun PA on catheter indwell time associated with catheter insertion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First attempt success rates (first stick success)</measure>
    <time_frame>Through study completion, an estimate of 1 year</time_frame>
    <description>Evaluate the effect of B. Braun PA on first attempt success rates (first stick success) associated with catheter insertion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aggregate costs associated with catheter insertion</measure>
    <time_frame>Through study completion, an estimate of 1 year</time_frame>
    <description>Evaluate the effect of B. Braun PA on aggregate costs associated with catheter insertion.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">632</enrollment>
  <condition>Complications Associated With Device</condition>
  <arm_group>
    <arm_group_label>Stage 1 Baseline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study site to use standard of care PIVC device(s) and procedure(s) on patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 Education</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>RN education and training in the use of B. Braun PIVC products, devices and procedures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 3 Run-In</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Familiarization of study RNs with the B. Braun devices and procedures in a clinical setting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 4 Post-Education</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study site uses B. Braun PIVC device(s) and procedure(s) on patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>B. Braun Peripheral Advantage (PA) Program</intervention_name>
    <description>B. Braun PA includes: Christie VeinViewer® Vision2 , Introcan Safety® IV Catheters, STEADYCare™ Smallbore Extension Set, and the PA Education</description>
    <arm_group_label>Stage 2 Education</arm_group_label>
    <arm_group_label>Stage 3 Run-In</arm_group_label>
    <arm_group_label>Stage 4 Post-Education</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hospital Standard of Care</intervention_name>
    <description>Standard of Care for PIVC access per hospital protocol</description>
    <arm_group_label>Stage 1 Baseline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RNs must complete all of the required B. Braun trainings in Stage 2 in order to
             participate in Stages 3 and 4.

        Subjects must meet all of the following Inclusion Criteria:

          1. Male or female aged ≥18 years;

          2. Able to understand and sign the Informed Consent Form (ICF);

          3. Have a medical condition that requires a PIVC lasting for at least 48 hours;

          4. Have intact skin at the site of insertion;

          5. If the patient has an existing IV in one arm he/she must have a viable contralateral
             arm for additional PIVC insertion.

        Exclusion Criteria:

        Subjects must not meet any of the following Exclusion Criteria:

          1. Are currently participating in another medical device or pharmaceutical study;

          2. In the opinion of the Investigator, would not be suitable candidates for this study;

          3. Are an employee of the Investigator or study center, have direct involvement in the
             study or other studies under the direction of that Investigator or study center, or
             are a family member of the employees or the Investigator;

          4. Have a laboratory confirmed bloodstream infection within 48 hours prior to
             participation in the study. The assessment is based on clinical observations and not
             routine for all subjects;

          5. Patient has an existing IV in one arm and has a medical condition prohibiting
             contralateral PIVC insertion.

          6. Was removed from any Stage of the study due to an AE associated with the PIVC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camilla M Jaekel, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic - La Crosse, WI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Valencia, MD</last_name>
    <phone>610-596-2875</phone>
    <email>diana.valencia@bbraunusa.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Flock</last_name>
      <email>flock.carolyn@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Janel Tunison</last_name>
      <email>tunison.janel@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imidacloprid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

